NCT/Study#

NCT04195750 /

MK-6482-005

An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1/L1 and VEGF-Targeted Therapies

An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1/L1 and VEGF-Targeted Therapies

DISEASE GROUP:
Genito-Urinary
current phase:
Phase III
STUDY STATUS:
Accepting Patients
Location:
Hackensack, NJ
For More information: